Liraglutide as a Potentially Useful Agent for Regulating Appetite in Diabetic Patients with Hypothalamic Hyperphagia and Obesity

被引：27

作者：

Ando, Takao ^{[1
]}

Haraguchi, Ai ^{[1
]}

Matsunaga, Tomoe ^{[1
]}

Natsuda, Shoko ^{[1
]}

Yamasaki, Hironori ^{[1
]}

Usa, Toshiro ^{[1
]}

Kawakami, Atsushi ^{[1
]}

机构：

[1] Nagasaki Univ, Grad Sch Biomed Sci, Dept Endocrinol & Metab, Nagasaki, Japan

来源：

INTERNAL MEDICINE | 2014年 / 53卷 / 16期

关键词：

GLP-1; hypothalamus; hyperphagia; obesity; satiety; GLUCAGON-LIKE PEPTIDE-1; BODY-WEIGHT; FOOD-INTAKE; GLP-1; BRAIN; RECEPTOR; SATIETY; ANALOG; ADULT;

D O I：

10.2169/internalmedicine.53.1646

中图分类号：

R5 [内科学];

学科分类号：

100201 [内科学];

摘要：

Hypothalamic hyperphagia and obesity are characterized by a lack of satiety and an abnormally high appetite that is difficult to control. We herein report the cases of two patients with hypothalamic hyperphagia and obesity with MRI-detectable hypothalamic lesions. These patients suffered from diabetes mellitus associated with an abnormal eating behavior and weight gain. Liraglutide was successfully used to treat their diabetes mellitus and suppress their abnormal appetites. Glucagon-like peptide-1 analogues, including liraglutide, are promising treatment options in patients with hypothalamic hyperphagia and obesity, as these agents enhance the hypothalamic input of the satiety signal, which is lacking in such patients.

引用

页码：1791 / 1795

页数：5

共 30 条

[1]

The inhibitory effects of peripheral administration of peptide YY3-36 and glucagon-like peptide-1 on food intake are attenuated by ablation of the vagal-brainstem-hypothalamic pathway [J].